On Thursday, PDC Energy Inc (NASDAQ:PDCE)’s shares declined -4.03% to $58.80.
PDC Energy Inc (PDCE) declared plans to host a conference call with investors to talk about first quarter 2015 results. Conference call materials will be accessible on the Company’s website, www.pdce.com, at the time of the call.
Conference Call and Webcast:
Date/Time: Thursday, May 7, 2015, 11:00 a.m. ET
PDC Energy, Inc., an independent exploration and production company, attains, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company operates in two segments: Oil and Gas Exploration and Production, and Gas Marketing.
Immune Design Corp (NASDAQ:IMDZ)’s shares dropped -3.98% to $26.55.
Immune Design Corp (IMDZ) declared the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $26.50 per share for total gross proceeds of about $79.5 million, before deducting underwriting discounts and commissions and estimated expenses. All of the shares of common stock are being offered by Immune Design. In addition, Immune Design has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock at the offering price, less underwriting discounts and commissions. The offering is predictable to close on April 21, 2015, subject to customary closing conditions.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms.
At the end of Thursday’s trade, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)‘s shares dipped -3.94% to $0.610.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has filed an application for a patent (European Patent Office precedingity application: EP15000132) on a novel method of manufacturing zoptarelin doxorubicin, its hybrid cytotoxic molecule that is the subject of a pivotal ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 clinical study in women with advanced, recurrent or metastatic endometrial cancer who have progressed and who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment). The claimed manufacturing process is predictable to result in a noteworthyreduction in the cost of goods sold, providing a stronger competitive position for the Company.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The companys product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Precision Drilling Corp (USA) (NYSE:PDS), ended its Thursday’s trading session with -3.92% loss, and closed at $7.10.
Precision Drilling Corp (USA) (PDS) intends to release its 2015 first quarter results before the market opens on Monday, April 27, 2015 and has planned a conference call and webcast to start promptly at 12:00 Noon MT (2:00 p.m. ET) on the same day.
Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company operates through two segments, Contract Drilling Services; and Completion and Production Services. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
